Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02812290 · ClinicalTrials.gov registry record

Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation

A clinical trial of Lung Transplant Rejection, sponsored by University of Alberta.

Recruiting
Registry status
700
Enrollment target
11
Study locations

NCT02812290: Recruiting study of Lung Transplant Rejection, sponsored by University of Alberta.

NCT02812290 is a study of Lung Transplant Rejection that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 700 participants, above the 544-participant average among 6 other Lung Transplant Rejection trials with a reported enrollment target (29% higher). The trial reports 11 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02812290, a study of Lung Transplant Rejection, is actively recruiting participants, sponsored by University of Alberta.

RECRUITING
Registry status
700 participants
Enrollment target
11
Study locations

Study Summary

Objective: To evaluate the potential impact of molecular phenotyping of transbronchial biopsies in lung transplant recipients with allograft dysfunction, and the potential for developing a safer endobronchial mucosal biopsy format.

Primary Outcome

Molecular classifier predicts antibody mediated and T cell mediated rejection, and chronic allograft dysfunction.

Conditions Studied

Interventions

  • PROCEDURE Lung transplant biopsy bites.

Study Locations (11)

Other

  • The Alfred Hospital, Monash University - Melbourne
  • Department of Thoracic Surgery, Medical University of Vienna - Vienna
  • Charles University/Hospital Motol - Prague
  • Thoracic Surgery Transplant Clinic - Szczecin

Alberta

  • Alberta Transplant Applied Genomics Centre, University of Alberta - Edmonton
  • Department of Medicine, University of Alberta - Edmonton

Arizona

  • St. Joseph's Hospital and Medical Center 350 West Thomas Road, Floor 8HLT - Phoenix

Maryland

  • University of Maryland School of Medicine - Baltimore

Missouri

  • Division of Pulmonary and Critical Care, Washington University School of Medicine - St Louis

Texas

  • University of Texas at San Antonio - San Antonio

Ontario

  • University Health Network, Toronto General Hospital - Toronto

Trial Details

FieldValue
Enrollment Target 700 participants
Start Date 2016-05
Est. Completion 2026-12
University of Alberta

19 total trials

What NCT02812290 shows while recruiting

NCT02812290 is an observational study that tracks outcomes without assigning an intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 544-participant average among 6 other Lung Transplant Rejection trials with a reported enrollment target (29% higher).

The record links to 1 condition, with Lung Transplant Rejection appearing as the primary indexed condition, and to 1 intervention - of which Lung transplant biopsy bites. is the first listed.

NCT02812290 lists 11 locations in 7 states (Other, Alberta, Arizona).

Frequently Asked Questions

What is clinical trial NCT02812290 about?

NCT02812290 is a clinical study titled "Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation". Objective: To evaluate the potential impact of molecular phenotyping of transbronchial biopsies in lung transplant recipients with allograft dysfunction, and the potential for developing a safer endobronchial mucosal biopsy format.

What is the current status of trial NCT02812290?

This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2016-05. Estimated completion is 2026-12.

What conditions does trial NCT02812290 study?

This clinical trial studies the following conditions: Lung Transplant Rejection.

What interventions are being tested in trial NCT02812290?

The interventions under investigation include: Lung transplant biopsy bites. (PROCEDURE).

Who is sponsoring clinical trial NCT02812290?

This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02812290 being conducted?

This trial has 11 study locations across Arizona, Maryland, Missouri, Texas, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Transplant Rejection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900419 · 700 participants

    Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

  • NCT01804686 · 700 participants · Phase 3

    A Long-term Extension Study of PCI-32765 (Ibrutinib)

  • NCT02107989 · 700 participants

    Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database

  • NCT02129543 · 700 participants

    Immune Reconstitution in Stem Cell Transplant Recipients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02812290, the US trial registry maintained by the National Library of Medicine. NCT02812290 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.